Genetic polymorphisms in CYP1A1, CYP1B1 and COMT genes in Greenlandic Inuit and Europeans

International Journal of Circumpolar Health

Volumn 72, Issue 1, 2013, Pages 1-9

  Ghisari, Mandana ^a   Long, Manhai ^a   Bonefeld Jørgensen, Eva C ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

COMT; Cytochrome P450; Genetic polymorphism; Inuit; PCBs; Persistent organic pollutants

Indexed keywords

EID: 84879302247     PISSN: 12399736     EISSN: 22423982     Source Type: Journal    
DOI: 10.3402/ijch.v72i0.21113     Document Type: Article

References (49)

1. Bozina N, Bradamante V, Lovric M. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh Hig Rada Toksikol. 2009;60:217-42.
2. Saillard J, Forster P, Lynnerup N, Bandelt HJ, Norby S. mtDNA variation among Greenland Eskimos: the edge of the Beringian expansion. Am J Hum Genet. 2000;67:718-26.
3. Deutch B, Hansen JC. High human plasma levels of organo chlorine compounds in Greenland. Regional differences and lifestyle effects. Dan Med Bull. 2000;47:132-7.
4. Bonefeld-Jorgensen EC. Biomonitoring in Greenland: human biomarkers of exposure and effects a short review. Rural Remote Health. 2010;10:1362.
5. Jonsson BA, Rylander L, Lindh C, Rignell-Hydbom A, Giwercman A, Toft G, et al. Inter-population variations in concentrations, determinants of and correlations between 2,2′,4,4′,5,5′-hexachlorobiphenyl (CB-153) and 1,1-dichloro-2,2-bis (p-chlorophenyl)-ethylene (p,p′-DDE): a cross-sectional study of 3161 men and women from Inuit and European populations. Environ Health. 2005;4:27.
6. Bonefeld-Jørgensen EC. Chapter 6 in AMAP assessment 2009: human health in the Arctic. Arctic Monitoring and Assessment Programmme (AMAP). Report No.: 13 978-82-7971-051-6. Oslo, Norway; 2009. Available from: http://www.amap.no/
7. Nebert DW, Dalton TP. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer. 2006;6:947-60.
8. Lai C, Shields PG. The role of interindividual variation in human carcinogenesis. J Nutr. 1999;129:552.
9. Crofts F, Taioli E, Trachman J, Cosma GN, Currie D, Toniolo P, et al. Functional significance of different human CYP1A1 genotypes. Carcinogenesis. 1994;15:2961-3.
10. Safe SH. Modulation of gene expression and endocrine response pathways by 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds. Pharmacol Ther. 1995;67:247-81. doi: 10.1016/0163-7258(95)00017-B.
11. Safe SH. Polychlorinated biphenyls (PCBs): environmental impact, biochemical and toxic responses, and implications for risk assessment. Crit Rev Toxicol. 1994;24:87-149. doi:10.3109/10408449409049308.
12. Uno S, Dalton TP, Derkenne S, Curran CP, Miller ML, Shertzer HG, et al. Oral exposure to benzo[a]pyrene in the mouse: detoxication by inducible cytochrome P450 is more important than metabolic activation. Mol Pharmacol. 2004; 65:1225-37.
13. Cascorbi I, Brockmoller J, Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res. 1996;56:4965-9.
14. Cosma G, Crofts F, Taioli E, Toniolo P, Garte S. Relationship between genotype and function of the human CYP1A1 gene. J Toxicol Environ Health. 1993;40:309-16.
15. Sergentanis TN, Economopoulos KP. Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. 2010;122:459-69.
16. Chen S, Xue K, Xu L, Ma G, Wu J. Polymorphisms of the CYP1A1 and GSTM1 genes in relation to individual susceptibility to lung carcinoma in Chinese population. Mutat Res. 2001;458:41-7.
17. Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev. 2001;10:1239-48.
18. Shimada T, Hayes CL, Yamazaki H, Amin S, Hecht SS, Guengerich FP, et al. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res. 1996;56:2979-84.
19. Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR. 17 Beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci USA. 1996;93:9776-81.
20. Buters JT, Sakai S, Richter T, Pineau T, Alexander DL, Savas U, et al. Cytochrome P450 CYP1B1 determines susceptibility to 7, 12-dimethylbenz[a]anthracene-induced lymphomas. Proc Natl Acad Sci USA. 1999;96:1977-82.
21. Shimada T, Watanabe J, Kawajiri K, Sutter TR, Guengerich FP, Gillam EM, et al. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 1999;20:1607-13.
22. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res. 2000;60:3440-4.
23. Li DN, Seidel A, Pritchard MP, Wolf CR, Friedberg T. Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. Pharmacogenetics. 2000;10:343-53.
24. Paracchini V, Raimondi S, Gram IT, Kang D, Kocabas NA, Kristensen VN, et al. Meta and pooled analyses of the cytochrome P-450 1B1 Val432Leu polymorphism and breast cancer: a HuGE GSEC review. Am J Epidemiol. 2007;165: 115-25.
25. Gajjar K, Martin-Hirsch PL, Martin FL. CYP1B1 and hormone-induced cancer. Cancer Lett. 2012;324:13-30.
26. Tunbridge EM. The catechol-O-methyltransferase gene: its regulation and polymorphisms. Int Rev Neurobiol. 2010;95: 7-27.
27. Merriam GR, MacLusky NJ, Picard MK, Naftolin F. Comparative properties of the catechol estrogens, I: methylation by catechol-O-methyltransferase and binding to cytosol estrogen receptors. Steroids. 1980;36:1-11.
28. Mueck AO, Seeger H. 2-Methoxyestradiol*biology and mechanism of action. Steroids. 2010;75:625-31.
29. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I, et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry. 1995;34:4202-10.
30. Dawling S, Roodi N, Mernaugh RL, Wang X, Parl FF. Catechol-O-methyltransferase (COMT)-mediated metabolism of catechol estrogens: comparison of wild-type and variant COMT isoforms. Cancer Res. 2001;61:6716-22.
31. Mao C, Wang XW, Qiu LX, Liao RY, Ding H, Chen Q. Lack of association between catechol-O-methyltransferase Val108/ 158Met polymorphism and breast cancer risk: a meta-analysis of 25,627 cases and 34,222 controls. Breast Cancer Res Treat. 2010;121:719-25.
32. Ding H, Fu Y, Chen W, Wang Z. COMT Val158Met polymorphism and breast cancer risk: evidence from 26 case-control studies. Breast Cancer Res Treat. 2010;123:265-70.
33. Xiao L, Tong M, Jin Y, Huang W, Li Z. The l58Val/Met polymorphism of catechol-O-methyl transferase gene and prostate cancer risk: a meta-analysis. Mol Biol Rep. 2013; 40:1835-41.
34. Palmatier MA, Kang AM, Kidd KK. Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles. Biol Psychiatry. 1999;46:557-67.
35. Risk TM-GCoGSfMHTRBC. Genetic polymorphisms in phase I and phase II enzymes and breast cancer risk associated with menopausal hormone therapy in postmenopausal women. Breast Cancer Res Treat. 2010;119:463-74.
36. Wen W, Cai Q, Shu X-O, Cheng J-R, Parl F, Pierce L, et al. Cytochrome P450 1B1 and catechol-O-methyltransferase genetic polymorphisms and breast cancer risk in Chinese women: results from the Shanghai breast cancer study and a meta analysis. Cancer Epidemiol Biomarkers Prev. 2005;14:329-35.
37. Bonefeld-Jorgensen EC, Long M, Bossi R, Ayotte P, Asmund G, Kruger T, et al. Perfluorinated compounds are related to breast cancer risk in Greenlandic Inuit: a case control study. Environ Health. 2011;10:88.
38. Cote S, Ayotte P, Dodin S, Blanchet C, Mulvad G, Petersen HS, et al. Plasma organochlorine concentrations and bone ultrasound measurements: a cross-sectional study in peri-and postmenopausal Inuit women from Greenland. Environ Health. 2006;5:33.
39. Bonefeld-Jorgensen EC, Hjelmborg PS, Reinert TS, Andersen BS, Lesovoy V, Lindh CH, et al. Xenoestrogenic activity in blood of European and Inuit populations. Environ Health. 2006;5:12.
40. Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, et al. Genetic variation in eleven phase I drugmetabolism genes in an ethnically diverse population. Pharmacogenomics. 2004;5:895-931.
41. Rudkowska I, Dewailly E, Hegele RA, Boiteau V, Dube-Linteau A, Abdous B, et al. Gene diet interactions on plasma lipid levels in the Inuit population. Br J Nutr. 2013;109:953-61.
42. Yao L, Fang F, Wu Q, Zhong Y, Yu L. No association between CYP1B1 Val432Leu polymorphism and breast cancer risk: a meta-analysis involving 40,303 subjects. Breast Cancer Res Treat. 2010;122:237-42.
43. Jefcoate CR, Liehr JG, Santen RJ, Sutter TR, Yager JD, Yue W, et al. Tissue-specific synthesis and oxidative metabolism of estrogens. J Natl Cancer Inst Monogr. 2000;95-112.
44. Gauger KJ, Giera S, Sharlin DS, Bansal R, Iannacone E, Zoeller RT. Polychlorinated biphenyls 105 and 118 form thyroid hormone receptor agonists after cytochrome P4501A1 activation in rat pituitary GH3 cells. Environ Health Perspect. 2007;115:1623-30.
45. Anwar-Mohamed A, Elbekai RH, El-Kadi AO. Regulation of CYP1A1 by heavy metals and consequences for drug metabolism. Expert Opin Drug Metab Toxicol. 2009;5:501-21.
46. van Duursen MB, Fernandez Canton R, Kocan T, Sanderson JT, Kieviet K, van den Berg M. No effect of CYP1B1 Val432Leu polymorphism on CYP1B1 messenger RNA levels in an organochlorine-exposed population in Slovakia. Cancer Epidemiol Biomarkers Prev. 2005;14:755-6.
47. Eriksson AL, Mellstrom D, Lorentzon M, Orwoll ES, Redlund-Johnell I, Grundberg E, et al. The COMT val158met polymorphism is associated with prevalent fractures in Swedish men. Bone. 2008;42:107-12 doi: 10.1016/j.bone.2007. 08.045.
48. Garner CE, Burka LT, Etheridge AE, Matthews HB. Catechol metabolites of polychlorinated biphenyls inhibit the catechol-O-methyltransferase-mediated metabolism of catechol estrogens. Toxicol Appl Pharmacol. 2000;162:115-23. doi: 10.1006/ taap.1999.8823.
49. La Merrill M, Harper R, Birnbaum LS, Cardiff RD, Threadgill DW. Maternal dioxin exposure combined with a diet high in fat increases mammary cancer incidence in mice. Environ Health Perspect. 2009;118:596-601.